Roche in $1.7bn deal for breast cancer innovator Seragon

Roche's Genentech business has agreed to pay $725m up front and up to $1bn in milestone-related payments to acquire Seragon Pharmaceuticals of San Diego, California. Seragon's most advanced product is in Phase I trials, but Roche believes its technology could herald a breakthrough in cancer treatment.